Sabrina Kay Appointed to MannKind Board of Directors
November 30 2020 - 8:00AM
MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay
Ed.D. has been appointed to its Board of Directors,
effective December 1, 2020. Dr. Kay will also serve
as a member of the Audit Committee of the Board. A serial
entrepreneur, tech educator, fashion designer, philanthropist, and
public speaker, Dr. Kay brings to MannKind a wealth
of experience in marketing, human capital development, finance and
executive leadership.
“We are excited to welcome Dr. Kay and
her years of invaluable leadership to our Board of Directors,”
said Kent Kresa, Chairman of the Board. “Her entrepreneurial
vision will be a critical asset for MannKind as the
company continues to evolve and the pipeline expands. Dr. Kay has a
successful track record in launching and leading a variety of
companies, and will add a fresh and diverse perspective as we
continue to pursue our mission to give people control of their
health and the freedom to live life.”
Currently, Dr. Kay serves as Founder and CEO of
Fremont Private Investments, where she has led the operations and
exits of several companies including The Art Institute of Hollywood
(sold to NASDAQ: EDMC), Premier Business Bank (sold to NASDAQ:
FFWM), Fashion Umbrella, Fremont College, and Dale Carnegie of Los
Angeles.
In addition to her success in the business
world, Dr. Kay is a philanthropist, having served on more than
30 charitable and civic boards. She is chairman of After-School
All-Stars Los Angeles, and a board member of the Los Angeles Sports
and Entertainment Commission, Petersen Automotive Museum, Portal
Schools, the Leadership Council of International Medical Corps
Leadership Council, and the Board of Leaders of USC Marshall
School. Dr. Kay has also chaired and spoken at numerous tech,
education, business, and leadership conferences, and taught
entrepreneurship programs at various universities.
Dr. Kay’s achievements have been recognized with
numerous awards, including the Education Award from
After-School All-Stars and the Humanitarian Award from
International Medical Corps. She was named Woman of the Year by
the California Legislature, Rising Asian Woman by the World
Affairs Council, and was a finalist for Entrepreneur of the
Year by Ernst & Young.
Dr. Kay received her joint doctorate degree in
Work-based Learning Leadership from the University of Pennsylvania.
She holds an MBA from the University of Southern California
and a Master of Science degree in education from
the University of Pennsylvania.
With the addition of Dr. Kay, there are
nine members of the MannKind Board of Directors.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development
and commercialization of inhaled therapeutic products for patients
with diseases such as diabetes and orphan lung
diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin
in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered
in Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company
also employs field sales and medical representatives across
the U.S. For further information,
visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will,"
"goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon MannKind's current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties detailed
in MannKind's filings with the SEC. For a discussion
of these and other factors, please refer to MannKind’s annual
report on Form 10-K for the year ended December 31, 2019 as
well as MannKind’s other filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press
release.
Company Contact: 818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024